IHC Marker-Myogenin Test
About IHC Marker-Myogenin Test
| Field | Value |
|---|---|
| Also Known As | Myogenin IHC, Myf-4 immunostain, Myogenic factor 4 IHC, Myogenin immunohistochemistry |
| Sample Type | Formalin-fixed, paraffin-embedded (FFPE) tissue (biopsy specimen) |
| Fasting Required | No |
| Report Time | 7 days |
| Recommended For | Individuals of all ages with suspected soft tissue tumours, particularly children and adolescents |
| Price | Starting at ₹1,920 |
What is an IHC Marker-Myogenin Test?
The IHC marker-Myogenin test is a specialised laboratory test that detects the presence of myogenin protein in a tissue sample. Myogenin is a myogenic regulatory protein primarily expressed in cells undergoing skeletal muscle differentiation, making it a highly useful marker in tumour diagnosis. Also known as Myogenin immunohistochemistry or Myf-4 immunostain, this test is performed on a biopsy specimen using a method called immunohistochemistry (IHC), where antibodies are used to highlight specific proteins in tissue.
What Does an IHC Marker-Myogenin Test Measure?
The IHC marker-Myogenin test procedure analyses tissue at the cellular level to detect a specific protein linked to skeletal muscle development. Here is what the test examines:
| Component | What It Tells the Pathologist |
|---|---|
| Myogenin protein expression | Whether cells in the tissue have skeletal muscle characteristics |
| Nuclear staining pattern | Confirms myogenin is active within the cell nucleus, indicating true muscle differentiation |
| Percentage of positive cells | Helps distinguish between different subtypes of rhabdomyosarcoma |
Why is an IHC Marker-Myogenin Test Done?
A doctor or oncologist may request IHC marker-Myogenin test when a tissue biopsy suggests a soft tissue tumour of uncertain origin. It plays a key role in identifying specific cancer types and ruling out others.
Common Symptoms That May Require This Test
Patients are typically referred for this test after a biopsy is taken. The symptoms that often prompt investigation include:
- An unexplained lump or mass in soft tissue
- A rapidly growing tumour, particularly in children
- Pain or swelling in the head, neck, limbs, or genital/urinary area
- Difficulty swallowing or breathing when a mass is present in the head or neck region
- Visible protrusion of a tumour through the skin
Conditions This Test Can Help Detect
The test is primarily used to identify or rule out the following conditions:
- Rhabdomyosarcoma (RMS): a malignant tumour of skeletal muscle differentiation that occurs predominantly in children and adolescents, although it can rarely occur in adults
- Alveolar rhabdomyosarcoma (ARMS): an aggressive subtype showing strong myogenin positivity in tumour cells
- Embryonal rhabdomyosarcoma (ERMS): a subtype with variable, lower-level myogenin staining
- Wilms tumour (nephroblastoma): particularly cases with myogenous differentiation
Myogenin staining is frequently used as part of an immunohistochemical panel to help distinguish rhabdomyosarcoma from other small round blue cell tumours such as Ewing sarcoma, neuroblastoma, and lymphoblastic lymphoma.
How to Prepare and What to Expect
The IHC marker-Myogenin test itself does not require any preparation from the patient. However, there are a few steps to be aware of before the biopsy procedure.
Do You Need to Fast?
No fasting is required for this test. The IHC staining process is performed entirely in the laboratory on a tissue sample that has already been collected.
Practical Tips Before Your Test
Keep the following in mind before undergoing the biopsy procedure:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test.
- Inform your doctor about all medications you are taking, especially blood thinners, as these may need to be paused before the biopsy.
- Wear loose, comfortable clothing to your biopsy appointment.
- Ask your doctor in advance whether local or general anaesthesia will be used, and follow any pre-procedure instructions given.
Step-by-Step Procedure
The overall process involves two stages: tissue collection (done with the patient present) and laboratory processing (done without the patient).
- A biopsy is performed by your doctor or surgeon. Depending on the tumour's location and size, tissue may be obtained through a core needle biopsy or surgical biopsy. In selected cases, cell-block material prepared from fine-needle aspiration specimens may also be suitable for immunohistochemical analysis.
- The collected tissue is placed in formalin solution to preserve it, then embedded in paraffin wax to form a firm block (called an FFPE block). This is the sample sent to the laboratory.
- The FFPE block is sliced into very thin sections and mounted onto glass slides.
- The tissue sections are treated with anti-myogenin antibodies. These antibodies are linked to a visible dye, which marks any myogenin protein present in the cells.
- A trained pathologist examines the stained slides under a microscope, assessing the presence, location, and extent of myogenin staining.
- The pathologist compiles the findings into a detailed report, which is sent to your referring doctor.
Factors That Can Affect Accuracy
Several factors can influence the reliability of the result:
- Quality of tissue fixation and processing after the biopsy
- Antibody quality used in the staining process
- Adequacy of the tissue sample (insufficient tissue may limit analysis)
- Use of proper positive and negative controls in the laboratory
- Experience and expertise of the interpreting pathologist
Understanding Your IHC Marker-Myogenin Test Results
Results from this test are qualitative, meaning they are reported as positive or negative rather than as a number. Your doctor and pathologist will interpret the result together with your clinical history and imaging findings.
| Result | What It May Indicate |
|---|---|
| Positive (nuclear staining present) | Suggests skeletal muscle differentiation and is most commonly associated with rhabdomyosarcoma |
| Strongly positive | May be seen more commonly in alveolar rhabdomyosarcoma, but subtype confirmation requires correlation with morphology and other IHC/molecular tests |
| Weakly or variably positive | May suggest embryonal rhabdomyosarcoma (ERMS) or Wilms tumour with myogenous elements |
| Negative | No myogenin expression detected; skeletal muscle origin is unlikely; other diagnoses should be considered |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
This is a diagnostic test used to identify specific tumour types rather than a routine health screening tool. General guidance includes:
- Attend all follow-up appointments as advised by your oncologist or treating doctor
- Share the full pathology report with your medical team so they can consider it alongside imaging and other findings
- Ensure any further recommended tests are completed promptly to support an accurate diagnosis
Lupin Diagnostics IHC Marker-Myogenin Test Price
The IHC marker-Myogenin test cost at Lupin Diagnostics starts at ₹1,920. This test requires a visit to a Lupin Diagnostics centre; home collection is not available, as the test requires a tissue biopsy performed by a trained medical professional.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 1920 |
| CHENNAI | 1920 |
| HYDERABAD | 1920 |
| KOLKATA | 1920 |
| NAVI MUMBAI | 1920 |
| PUNE | 1920 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book your IHC marker-Myogenin test online:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within 7 days.
Frequently Asked Questions
The IHC marker-Myogenin test detects the myogenin protein in tumour tissue, which is a marker of skeletal muscle differentiation. It is primarily used to diagnose rhabdomyosarcoma and to distinguish it from other soft tissue tumours that may look similar under the microscope.
The tissue sample is obtained through a biopsy. Depending on the size and location of the tumour, this may be a needle biopsy or a surgical procedure performed under local or general anaesthesia. The patient does not need to be present for the laboratory staining process itself.
No fasting or dietary restrictions are required. You should inform your doctor about any medications you are taking, particularly blood thinners. Bringing a complete clinical history, including previous test results and imaging reports, is essential as it is required for accurate interpretation of findings.
A positive myogenin result is a strong indicator of rhabdomyosarcoma, but it is not used in isolation. Diagnosis requires correlation with clinical history, imaging findings, and typically a panel of additional IHC markers.
While rhabdomyosarcoma is most common in children and adolescents, the test can be ordered for patients of any age when a soft tissue tumour with possible skeletal muscle origin is identified. Your doctor will advise whether this test is appropriate based on your specific biopsy findings.
No. This test requires a tissue biopsy, which must be performed at a hospital or diagnostic centre by a trained medical professional. Home sample collection is not possible for this test.
The IHC staining process itself is carried out entirely in the laboratory and does not involve the patient. The only step requiring patient involvement is the initial biopsy, during which anaesthesia is used. Any discomfort is related to the biopsy procedure and is managed by the treating medical team.
IHC Marker-Myogenin Test: Booking, Price, and Results
